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A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung
cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20Gy/5 fractions (fr)/5 days (arm A) or 16Gy/2 fr/day
1 and 8 (arm B). There were 90 men and 10 women aged 47–81 years (mean 66), performance status 1–4 (median 2). The major
clinical characteristics and incidence and degree of initial disease-related symptoms were similar in both groups. Treatment effects
were assessed using patient’s chart, doctor’s scoring of symptomatic change and chest X-ray. Study end points included degree and
duration of symptomatic relief, treatment side effects, objective response rates and overall survival. A total of 55 patients were
assigned to arm A and 45 to arm B. In all, 98 patients received assigned treatment, whereas two patients died before its termination.
Treatment tolerance was good and did not differ between study arms. No significant differences between study arms were observed
in the degree of relief of all analysed symptoms. Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3
months; P¼0.016). Both irradiation schedules provided comparable, effective palliation of tumour-related symptoms. The improved
overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic
inoperable NSCLC.
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Lung cancer is the most common human malignancy worldwide,
accounting for 1.2 million new cases and 1.1 million deaths a year
(Parkin, 2001). Most patients present with inoperable tumour and
the majority of disease symptoms are related to its local
progression. In non-small-cell lung cancer (NSCLC) patients not
suitable for surgery or radical (chemo)radiotherapy, the main aim
of treatment is palliation. In these patients, palliative radiotherapy
remains the main therapeutic modality. Given the short expected
survival, treatment of these patients should be short and
nondistressing (Durrant et al, 1971; Sundstrom et al, 2004). Over
the last 30 years, several attempts have been made to develop
treatment schedules combining effective symptom control and
short treatment time. The benefits of such an approach include
better comfort of patients having anyway short expected survival,
and savings on the use of radiotherapy equipment, a resource still
deficient in many countries. Additionally, shorter treatments
generally allow hospitalisation to be avoided and enable earlier
improvement of symptoms (Kowalska, 1992). The equivalence of
shorter vs longer radiotherapy schemes in terms of symptom
control was demonstrated in a series of randomised studies
(Simpson et al, 1985; Medical Research Council Lung Cancer
Working Party, 1991; Medical Research Council Lung Cancer
Working Party, 1992; Abratt et al, 1995; Nestle et al, 2000; Kramer
et al, 2003; Sundstrom et al, 2004). Nevertheless, doubts still exist
regarding the potentially detrimental impact of shorter regimens
on overall survival, particularly in patients with good performance
status. In consequence, in many institutions this method has not
been accepted as a standard of care. The aim of our study was to
add to the evidence on the feasibility and equivalence of a 2-
fraction (fr) vs commonly used 5-fraction regimen in terms of
palliation of thoracic symptoms, toxicity and survival in the hope
of optimising treatment practice in our country.
In the coordinating centre, hypofractionated radiotherapy in the
palliative treatment of NSCLC was introduced in 1990. In a pilot
study, a dose of 24Gy in 3 fractions delivered on days 1, 8 and 22
was used (Drozd-Lula et al, 1996). The drawback of this regimen,
however, was the long overall treatment time and concern about
the relatively high dose to the spinal cord. Additionally, in most
patients palliative effect was already observed after two fractions,
and many were spared the third fraction. The last fraction was also
abandoned in patients progressing after the first two fractions
(Drozd-Lula et al, 1996). As a result, experience was gained with
the dose of 16Gy in 2 fractions 1 week apart, which was then
chosen as the experimental arm for the current study. The control
arm (20Gy in 5 fractions over 5 consecutive days) was the regimen
of palliative lung cancer irradiation most frequently used in
Poland.
Revised 1 January 2005; accepted 31 January 2005; published online 15
March 2005
*Correspondence: Dr E Senkus-Konefka; E-mail: elsenkus@amg.gda.pl
British Journal of Cancer (2005) 92, 1038–1045
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.com
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sMATERIALS AND METHODS
Eligibility criteria included cytologically or histopathologically
confirmed NSCLC not suitable for radical treatment by surgery or
radiotherapy, the presence of symptoms related to chest tumour
(cough, dyspnoea, haemoptysis, chest pain, dysphagia or superior
vena cava syndrome (SVCS)), age 418 years, WHO performance
status X1, expected survival of at least 3 months and written
informed consent. Patients with both locally advanced and
metastatic disease were allowed to participate. Ineligibility criteria
included previous chest radiotherapy, systemic anticancer therapy
given concurrently or planned within the next 6 weeks and
difficulties expected with follow-up or with completing the ‘patient
questionnaires’. Local ethics committee approval of the protocol
was required.
Patients were randomised to receive 20Gy in 5 fractions over 5
consecutive days (arm A) or 16Gy in 2 fractions 1 week apart (arm
B). Randomisation was conducted by means of a dedicated
computer program, after stratification for treating centre, perfor-
mance status (PS) and extent of disease.
Baseline examinations included history and physical examina-
tion, full blood count, chest X-ray and completion of the ‘patient
questionnaire’. Doses of radiotherapy were prescribed to the mid-
point without air correction, using two parallel-opposed mega-
voltage fields. No spinal cord shielding was used.
Primary end points included degree and duration of relief of
chest tumour-related symptoms, as assessed by patients and
physicians. Secondary end points were treatment side effects,
objective response and overall survival. Assessed symptoms of
chest tumour included cough, dyspnoea, haemoptysis, chest pain,
dysphagia, SVCs or ‘other’ and were evaluated both by patients (at
baseline, weekly for 8 weeks and then during follow-up visits) and
by physicians (at baseline and during follow-up visits). The
grading of symptom intensity was performed using a 4-point scale
(none, mild, moderate, severe). The duration of improvement was
expressed by the number of assessments (not necessarily
consecutive) with symptomatic improvement recorded by the
patient. Such a method was chosen to allow for variability of
treatment effect over time. Physician assessment included also
categorical estimation of the overall treatment effect (complete
symptomatic response, improvement, no change or worsening of
symptoms).
Follow-up visits were scheduled monthly for the first 6 months,
bimonthly for the next 6 months and every 3 months thereafter.
Chest X-rays were repeated bimonthly or when clinically indicated.
In the case of poor response to radiotherapy or progression of
symptoms, further treatment was left to the discretion of the
treating physician.
Assuming a 50% improvement rate in the control arm (20Gy/5
fr), to detect the difference in efficacy greater than 15% with a
significance level of 0.05 and power of 80% with a two-sided test,
the required number of evaluable patients in both arms was 292, or
a total of 321 patients (assuming 10% dropout rate). With the
expected accrual of 100 patients per year, the trial was scheduled to
close in 4 years.
All analyses were performed according to the ‘intention-to-treat’
principle. Categorical data were analysed with the use of w
2 test or
Fisher’s exact test. Continuous data were analysed with Mann–
Whitney U-test. The mean symptom scores (assessed by patient
questionnaires) together with its 95% confidence intervals were
plotted to analyse symptomatic improvement with time and
according to study group. Survival analysis was performed with
Kaplan–Meier method. Survival time was calculated from the date
of randomisation until the date of death, survivors being censored
at the last date known to be alive. Groups were compared with log-
rank test in the univariate analysis. Cox’s proportional hazard
model was used for multivariate analysis with forward-stepwise
regression based on Wald’s statistic. Type I error of 0.05 was used
for hypothesis testing with no adjustments for multiple compar-
isons.
RESULTS
Between September 1997 and April 2000, 100 patients (55 in 20Gy/
5 fr arm and 45 in 16Gy/2 fr arm) from eight Polish centres were
entered into the trial. The trial was closed prematurely due to
decreasing accrual. There were 90 men and 10 women aged 47–81
years (median 66), PS 1–4 (median 2). In all, 84 patients had
locally advanced tumour and 16 patients additionally had
metastatic lesions outside the thorax. Squamous cell carcinoma
was diagnosed in 65 patients, adenocarcinoma in nine, large cell
carcinoma in one and unspecified NSCLC in 25. There was no
significant difference in the distribution of patient characteristics
between the two treatment groups (Table 1) and neither was there
a major difference in the incidence and degree of initial disease-
related symptoms (Table 2).
A total of 98 patients received assigned treatment, whereas two
patients died before its completion. Treatment portals did not
differ between treatment arms (20Gy/5 fr: mean 150cm
2, range
100–222cm
2; 16Gy/2 fr: mean 146cm
2, range 80–218cm
2;
P¼0.49).
A total of 58 patients (73% of 80 patients surviving more than 2
months) returned the questionnaire inquiring about their symp-
toms during the first 8 weeks after the randomisation and were
therefore evaluable for symptomatic response. Compliance was
similar in both treatment groups (P¼0.48). The physician
assessment of treatment effect was available for 57 patients and
radiological assessment of tumour regression for 47 patients.
Treatment tolerance was good and did not differ between the
study arms. Side effects in the control and study arms, as reported
by treating physicians, included oesophagitis (respectively 12.5
and 24%, P¼0.30), pneumonitis (respectively 3 and 4%, P¼1.00),
chest pain (respectively 3 and 4%, P¼1.00) and skin reactions
(respectively 3 and 4%, P¼1.00). There were no detected cases of
radiation myelopathy.
The percentages of all evaluable patients reporting any
symptomatic improvement were as follows: cough 51% (24 out
of 47; for a median of six assessments, range: 1–10), dyspnoea 60%
Table 1 Patient characteristics at randomisation
Patient’s characteristics 20Gy/5 fr 16Gy/2 fr P
Gender
Male 48 42 0.51
Female 7 3
Age (years)
Median 67 66 0.73
Range 47–81 52–79
Disease extent
Locally advanced 45 39 0.70
Metastatic 10 6
Pathology
Squamous cell 35 30 0.62
Adenocarcinoma 6 3
Large cell — 1
Unspecified NSCLC 14 11
WHO performance status
PS 1 17 22 0.16
PS 2 27 18
PS 3 8 5
PS 4 3 —
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s(26 out of 43; for a median of six assessments, range: 1–9),
haemoptysis 86% (19 out of 22; for a median of eight assessments,
range: 1–11), chest pain 83% (34 out of 41; for a median of four
assessments, range: 1–9), dysphagia 71% (five out of seven; for a
median of eight assessments, range: 1–9), SVCS 83% (five out of
six; for a median of five assessments, range: 4–9). The numbers of
patients achieving symptomatic improvement did not differ
between study groups for all analysed symptoms (Table 3). The
mean symptom scores at specified time intervals after treatment
start are presented in Figures 1–6. Consistently with percentage of
patients reporting symptomatic improvement, the degree of
improvement (reduction of symptom score) was highest for
haemoptysis and chest pain, and did not differ between study
groups, as indicated by overlapping confidence intervals at specific
points of time. No difference was also noted between study arms
for degree of improvement of dyspnoea, cough and SVCS. Not
surprisingly, mean dysphagia scores were higher shortly after
Table 2 Initial symptoms of chest tumour
Symptom 20Gy/5 fr 16Gy/2 fr P
Cough
Mild 15 14 0.65
Moderate 14 16
Severe 2 1
Dyspnoea
Mild 10 9 0.32
Moderate 13 17
Severe 9 3
Haemoptysis
Mild 9 6 0.62
Moderate 9 5
Severe 1 2
Chest pain
Mild 8 13 0.44
Moderate 17 11
Severe 7 5
Dysphagia
Mild 5 1 0.14
Moderate 1 —
Severe — 2
SVCS
Mild 2 2 0.82
Moderate 1 1
Severe 1 —
Table 3 Numbers of patients reporting symptomatic improvement by treatment group
20Gy/5 fr 16Gy/2 fr
Symptom
Number
improving
Median number of
assessments with
improvement (range)
Number
improving
Median number of
assessments with
improvement (range) P
Cough 12/26 (46%) 6 (1–8) 12/21 (57%) 6 (1–10) 0.45
Dyspnoea 13/23 (54%) 4 (1–8) 13/20 (65%) 6 (1–9) 0.57
Haemoptysis 12/15 (80%) 7 (1–10) 7/7 (100%) 8 (1–11) 0.52
Chest pain 20/24 (83%) 4 (1–9) 14/17 (82%) 4 (1–8) 1.00
Dysphagia 2/3 (67%) 3 (1–4) 3/4 (75%) 8 (8–9) 1.00
SVSC 2/2 (100%) 7 (5–9) 3/4 (75%) 5 (4–7) 1.00
Note: denominators of numbers of patients improving in each group may differ from data included in Table 2, as only patients with available follow-up were included in the
analysis.
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Figure 1 Patients’ self-assessment of cough, according to treatment arm
and week of follow-up. Boxplots represent mean 795% confidence
interval; N¼number of patients.
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Figure 2 Patients’ self-assessment of dyspnoea, according to treatment
arm and week of follow-up. Boxplots represent mean 795% confidence
interval; N¼number of patients.
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according to treatment arm.
No differences in the overall treatment effects as assessed by
treating physicians or in the objective response on chest X-ray
were observed (Table 4).
During the follow-up period, eight patients (15%) from the
20Gy/5 fr group and three (7%) from the 16Gy/2 fr group required
additional thoracic radiotherapy after a median of, respectively, 3.5
months (range 3–15 months) and 2 months (range 1–4 months).
Three and two patients, respectively, from each arm, were referred
for palliative chemotherapy.
Of the 100 patients, 98 have died and two were lost to follow-up.
Overall survival time differed significantly between the study
groups in favour of 16Gy/2 fr (median 8.0 months), compared to
20Gy/5 fr (median 5.3 months), P¼0.016 (Figure 7). In all, 6- and
12-month survival probabilities were 57% (95% CI: 42–72%) and
27% (95% CI: 14–40%) for patients receiving 16Gy/2 fr, and 30%
(95% CI: 18–42%) and 11% (95% CI: 3–20%) for patients
receiving 20Gy/5 fr, respectively. This difference remained
significant after correction for disease extent (P¼0.022) and
performance status (P¼0.007). Univariate analysis of overall
survival according to disease extent, performance status, initial
symptoms and radiation treatment is presented in Table 5. Apart
from treatment regimen, dysphagia at presentation was the only
unfavourable prognostic factor in the univariate analysis
(Po0.001). In the multivariate analysis, schedule of radiation
remained the only prognostic variable, with a hazard ratio of 1.65
(95% CI: 1.09–2.48) for patients administered 20Gy in 5 fractions
as compared to patients who received 16Gy/2 fr (P¼0.017).
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Figure 3 Patients’ self-assessment of haemoptysis, according to treat-
ment arm and week of follow-up. Boxplots represent mean 795%
confidence interval; N¼number of patients.
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Figure 4 Patients’ self-assessment of chest pain, according to treatment
arm and week of follow-up. Boxplots represent mean 795% confidence
interval; N¼number of patients.
N = 3 22 82 62 1 2 32 31 91 6
8 4 2 0 8 4 2 0
Arm A = 20 Gy/5 fr Arm B = 16 Gy/2 fr
Week
1.2
1.0
0.8
0.6
0.4
0.2
0.0
−0.2
D
y
s
p
h
a
g
i
a
Figure 5 Patients’ self-assessment of dysphagia, according to treatment
arm and week of follow-up. Boxplots represent mean 795% confidence
interval; N¼number of patients.
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Figure 6 Patients’ self-assessment of superior vena cava syndrome,
according to treatment arm and week of follow-up. Boxplots represent
mean 795% confidence interval; N¼number of patients.
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sDISCUSSION
The issue of optimal palliative irradiation schedule in symptomatic
NSCLC has been a subject of numerous prospective randomised
studies (Table 6) (Medical Research Council Lung Cancer Working
Party, 1991; Medical Research Council Lung Cancer Working
Party, 1992; Simpson et al, 1985; Teo et al, 1988; Abratt et al, 1995;
Macbeth et al, 1996; Rees et al, 1997; Reinfuss et al, 1999; Nestle
et al, 2000; Gaze et al, 2001; Bezjak et al, 2002; Kramer et al, 2003;
Sundstrom et al, 2004). Although the comparison of these trials is
difficult due to differences in the radiotherapy regimens, patient
characteristics and outcome measures, there is no strong evidence
for the superiority of any particular regimen (Hansen, 2002;
Macbeth et al, 2004). Probably the most important and influential
trials were those conducted consecutively in the UK by the Medical
Research Council (MRC). These studies were first to demonstrate
the feasibility and efficacy of very short radiotherapy regimens of
two fractions of 8.5Gy (Medical Research Council Lung Cancer
Working Party, 1991) or one fraction of 10Gy (Medical Research
Council Lung Cancer Working Party, 1992). The results of these
studies were generally confirmed by subsequent trials (Simpson
et al, 1985; Abratt et al, 1995; Macbeth et al, 1996; Rees et al, 1997;
Nestle et al, 2000; Kramer et al, 2003; Sundstrom et al, 2004) and
are in agreement with the results of our study. Importantly, like all
these studies, we used relatively simple treatment planning system
rather than sophisticated three-dimensional methods used in
protracted radiotherapy regimens. Indeed, these easy to administer
and nontoxic regimens resulted in effective and durable palliation of
main symptoms (Medical Research Council Lung Cancer Working
Party, 1991; Medical Research Council Lung Cancer Working Party,
1992; Sundstrom et al, 2004). These results, however, were
challenged by a few studies, which demonstrated better palliation
in patients given higher radiation doses (Teo et al, 1988; Gaze et al,
2001; Bezjak et al, 2002). These discrepancies can at least partially be
explained by various end points and differences in evaluation tools
used in particular studies (Bezjak et al, 2002). In particular, many
studies emphasised the importance of relying (as we did) more on
patient self-assessment than on physicians’ evaluation, as major
differences are observed between results of both these judgments
(Macbeth et al,1 9 9 6 ;S t o u tet al, 2000; Sundstrom et al,2 0 0 4 ) .
The major concern related to the use of hypofractionated
treatment schedules is their potential inferiority in terms of overall
survival (Macbeth et al, 1996; Bezjak et al, 2002). Some evidence
exists that higher radiotherapy doses result in a modest increase in
survival, although at the expense of higher acute toxicity (Macbeth
et al, 1996; Reinfuss et al, 1999; Bezjak et al, 2002; Kramer et al,
2003; Macbeth et al, 2004; Sundstrom et al, 2004). The effect of
radiotherapy dose and regimen on overall survival, if any, was in
all instances limited to patients with good PS and/or relatively
nonadvanced disease, that is, those most likely to benefit from
improved local control (Kowalska, 1992; Macbeth et al, 1996;
Reinfuss et al, 1999; Bezjak et al, 2002; Sundstrom et al, 2004). In
contrast to these results, our study demonstrated improved
survival in the shorter treatment arm and this difference remained
Table 4 Physician and radiologic assessment of therapeutic effect by
treatment group
20Gy/5 fr 16Gy/2 fr P
Physician assessment
Complete symptomatic response 6 (19%) 4 (16%) 0.69
Improvement 17 (53%) 15 (60%)
No change 5 (16%) 5 (20%)
Worsening of symptoms 4 (12%) 1 (4%)
Radiologic assessment
Complete response — — 0.99
Partial response 12 (52%) 13 (54%)
No change 7 (31%) 7 (29%)
Progression 4 (17%) 4 (17%)
36 33 30 27 24 21 18 15 12 9 6 3 0
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Arm A: median OS = 5.3 months
Arm B: median OS = 8.0 months
Log-rank P = 0.016
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Figure 7 Survival according to treatment group (n¼100).
Table 5 Univariate analysis of overall survival (OS)
N Median OS (months) 95% CI P (log-rank)
Disease extent
Locally advanced 84 5.6 (5.0–6.2) 0.115
Metastatic 16 4.2 (0.8–7.6)
Performance status
1 39 5.5 (5.2–5.8) 0.091
2 45 5.7 (3.7–7.6)
42 16 3.8 (1.5–6.2)
Cough
No 17 6.0 (5.2–6.7) 0.586
Yes 62 5.3 (4.4–6.1)
Dyspnoea
No 18 5.6 (4.6–6.5) 0.624
Yes 61 5.4 (4.4–6.4)
Haemoptysis
No 47 5.5 (5.1–5.8) 0.738
Yes 32 5.4 (1.1–9.7)
Chest pain
No 18 4.8 (2.5–7.0) 0.333
Yes 61 5.6 (4.9–6.3)
Dysphagia
No 70 5.9 (4.7–7.0) o0.001
Yes 9 4.3 (0.0–9.7)
SVCS
No 72 5.4 (4.8–6.1) 0.365
Yes 7 5.6 (2.0–8.3)
Treatment arm
20Gy/5 fr 55 5.3 (4.6–6.0) 0.016
16Gy/2 fr 45 8.0 (4.5–11.4)
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Reference Treatment schedules Entry criteria Treatment tolerance Palliative effect Overall survival
MRC I (1) 30Gy/10  vs 17Gy/2  Locally advanced NSCLC
(including M+)
No difference No difference No difference
MRC II (2) 17Gy/2  vs 10Gy/1  PSX2, inoperable NSCLC
(including M+)
More dysphagia with 17Gy/2  No difference No difference
Rees (3) 22.5Gy/5  vs 17Gy/2  Lung cancer suitable for palliative
chest RT
Trend for more dysphagia with
17Gy/2 
Trend for better control of chest
pain and cough in 17Gy/2 
No difference
MRC (4) 39Gy/13  vs 17Gy/2  Locally advanced NSCLC, PS 0–2 More dysphagia with 39Gy/13  More rapid palliation in 17Gy/
2 
Improved OS in 39Gy/13 
RTOG (5) 40Gy/10  (split course) vs
30Gy/10  vs 40Gy/20 
Locally advanced NSCLC,
Karnofsky X60
More pneumonitis with 40Gy/
10  (split course)
No difference No difference
Reinfuss (6) 50Gy/25  vs 40Gy/10  (split
course) vs observation
Stage III, unresectable,
asymptomatic NSCLC
More grade 2 oesophagitis with
40Gy/10  (split course)
NA Improved OS in 50Gy/25 
Nestle (7) 60Gy/30  vs 32Gy/16  (bid) Inoperable NSCLC (stage III or
‘minimal’ IV), Karnofsky X50
Earlier oesophagitis with 32Gy/
16  (bid)
No difference No difference
Abratt (8) 45Gy/15  vs 35Gy/10  Stage III NSCLC not suitable for
radical RT
More oesophagitis with 45Gy/
15 
No difference No difference
Teo (9) 45Gy/18  vs 31.2Gy/4  Inoperable NSCLC not suitable for
radical RT (including M+)
No difference Better palliation in 45Gy/18  No difference
NCIC CTG SC.15
(10)
20Gy/5  vs 10Gy/1  Locally advanced NSCLC
(including M+)
No difference Better palliation in 20Gy/5  Improved OS in 20Gy/5 
Gaze (11) 30Gy/10  vs 10Gy/1  Advanced NSCLC Not reported Better palliation in 30Gy/10  No difference
Sundstrom [Z] 50Gy/25  vs 42Gy/15  vs
17Gy/2 
Locally advanced NSCLC
(including M+)
Less and later occurrence of
dysphagia with 50Gy/25 arm
No difference No difference
Dutch [Y] 30Gy/10  vs 16Gy/2  Locally advanced NSCLC
(including M+)
More complains in 16Gy/2  Earlier response in 16Gy/2  Improved OS in 30Gy/10 
Current study 20Gy/5  vs 16Gy/2  Locally advanced NSCLC
(including M+)
No difference No difference Improved OS in 16Gy/2 
M+¼metastatic, MRC¼Medical Research Council, NA¼not applicable, NCIC¼National Cancer Institute of Canada, NSCLC¼non-small-cell lung cancer, OS¼overall survival, PS¼performance status, RT¼radiotherapy,
RTOG¼Radiation Therapy and Oncology Group.
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Clinical Studiessignificant after correction for disease extent and performance
status. This intriguing result should, however, be interpreted with
caution due to relatively small number of patients in the study arms.
Performance status and disease stage, of confirmed prognostic value
in other studies (Medical Research Council Lung Cancer Working
Party, 1991; Kowalska, 1992), had no independent impact on overall
survival in our series. It is possible that the survival difference in
this study was associated with some undiscovered imbalance
between treatment groups due to small sample size caused by
premature termination of the study and its simple and pragmatic
design (e.g., no detailed TNM staging was requested). The
imbalance in the number of PS 3 or 4 patients between both study
groups, although not statistically significant by Pearson’s w
2 test
(with small numbers in subgroups), might have potentially
translated into survival difference. As mentioned, PS did not,
however, affect survival in univariate or multivariate analysis. It
would be difficult to find another explanation for improved survival
in patients receiving less treatment, although in two other studies a
trend toward improved survival in the lower dose group was
observed in a subset analysis (Nestle et al, 2000; Sundstrom et al,
2004). It seems reassuring that such a short treatment is at least not
inferior in terms of survival, compared to a standard schedule.
As a result of published trials, a general conclusion was made
(and became a basis for official recommendations) that selected
advanced and symptomatic NSCLC patients should be treated with
just 1 or 2 fractions of palliative radiotherapy (American Society of
Clinical Oncology, 1997; Jassem, 2001; Macbeth et al, 2004). Such a
policy has been widely adopted in the United Kingdom (Priestman,
1996), but not in many other parts of the world (Bezjak et al, 2002).
Apart from purely medical factors, such an approach has obvious
logistic and economical benefits, which is of particular importance
in countries with limited health care resources. Commonly used
treatment schedules are still, however, more often based on
tradition than on clinical research results (Macbeth et al, 2004). In
particular countries treatment policy is a subject of different
societal, cultural, attitudinal and health service delivery influences
(Bezjak et al, 2002). The sources of reluctance toward hypofrac-
tionated regimens include the lack of experience with large single
fraction, concerns about its acute toxicity and uncertainty about
the appropriate patient selection for hypofractionated therapy
(Bezjak et al, 2002). The main rationale for the use of larger
radiotherapy doses and longer fractionation schemes, apart from
potential survival gain, is improvement in local control leading to
better quality of life (Macbeth et al, 1996). Indeed, in some studies
during long follow-up, better palliative effect was observed in
patients applied protracted schedules (Macbeth et al, 1996). On the
other hand, short regimens allow for more rapid symptom control
(Macbeth et al, 1996). As one of the aims of palliative radiotherapy
is psychological support, another worry related to the use of very
short fractionation regimens is their potentially negative effect on
patients’ psychological functions, such as levels of anxiety or
depression (Falk et al, 2002). In one study, increased anxiety was
observed in patients treated with one fraction, compared to those
administered 10 fractions (Gaze et al, 2001). No negative effect on
anxiety, depression or psychological distress was seen, however, in
patients assigned to delayed rather than immediate radiotherapy in
the MRC study (Falk et al, 2002). These differences could possibly
have been caused by varying use of other, complementary methods
of psychological support (Falk et al, 2002).
The efficacy of palliative radiotherapy depends on the type of
predominant symptom. Several studies, including the present one,
demonstrated that the most effectively palliated symptoms include
haemoptysis and chest pain (Simpson et al, 1985; Macbeth et al,
1996; Rees et al, 1997; Cross et al, 2004; Sundstrom et al, 2004). In
some studies, irradiation also resulted in effective relief of cough –
the symptom least effectively palliated in our series, as well as in
the recently reported Norwegian study (Rees et al, 1997;
Sundstrom et al, 2004). It is of note that radiotherapy was also
found to relieve effectively general symptoms (not directly related
to chest tumour), like lack of energy, tiredness or anorexia
(Medical Research Council Lung Cancer Working Party, 1991;
Macbeth et al, 1996; Cross et al, 2004). This treatment modality
seems to be least effective for dyspnoea, which in some patients
may be related to irreversible lung damage caused by pulmonary
collapse or consolidation (Simpson et al, 1985; Stout et al, 2000;
Langendijk et al, 2001; Cross et al, 2004).
The modern definition of palliation (as recommended by the
MRC Cancer Trials Office) encompasses symptom improvement
(reduction of existing moderate or severe symptoms), control (no
deterioration in mild symptoms) and prevention (no deterioration
in those with no symptoms) (Stephens et al, 1999). Such a
comprehensive assessment is particularly important in the setting
of lung cancer, a tumour typically accompanied by multiple
symptoms (Bezjak et al, 2002). Our study was initiated before these
recommendations were published and was designed to measure
predominantly the degree of symptomatic improvement. Never-
theless (although not planned in the study protocol), the evaluation
of the mean score of symptom intensity encompassed also the
development of new symptoms and allowed for some estimate of
the efficacy of compared treatments in their control and prevention.
An unanswered question remains the optimal management of
asymptomatic or minimally symptomatic NSCLC patients not
suitable for radical treatment, in whom one of the options is
watchful waiting. The argument for early treatment in these
patients is that enhanced local control may prolong survival and
improve quality of life by delaying development of thoracic
symptoms (Falk et al, 2002). The results of randomised studies
testing early vs delayed or ‘as required’ radiotherapy in this group
of patients are contradictory (Roswit et al, 1968; Durrant et al,
1971; Reinfuss et al, 1999; Falk et al, 2002). A Polish study
demonstrated a major difference in overall survival in favour of
early treatment (Reinfuss et al, 1999), whereas in the recent MRC
trial no differences in main outcome measures, including overall
survival, were observed (except for a delay in the development of
severe or moderate symptoms in the early treatment group) (Falk
et al, 2002). Importantly, 58% of patients in the ‘delayed treatment’
group never needed thoracic radiotherapy (Falk et al, 2002;
Hansen, 2002). The observed discrepancies in patient survival may
result from patient selection or differences in radiotherapy
regimen used (relatively high doses in the Polish study vs 1–2
fractions in the MRC study). It is also possible that patients in early
irradiation groups might possibly have been offered better
supervision and supportive care (Roswit et al, 1968; Reinfuss
et al, 1999; Falk et al, 2002).
Our trial was closed prematurely due to decreasing accrual of
patients. As in other similar studies, this poor outcome might
partially be due to the increasing application of palliative
chemotherapy, which has recently come into widespread use in
this population of patients (Langendijk et al, 2001; Cross et al,
2004). The limited number of patients accrued into the study
obviously decreases its statistical power to detect potential
differences in outcome. The early closure of the study also resulted
in the unequal numbers of patients in both arms. Indeed, the
design of randomisation method (randomisation in blocks after
stratification) was created to assure balance between originally
planned, larger groups of patients. A number patients in this series
was diagnosed using fine-needle aspiration biopsy of primary
tumour or peripheral lymph nodes, thus creating a relatively large
proportion of unclassified NSCLCs. In fact, no attempt was made
to specify the diagnosis further, as this would have had no
therapeutic implications. Another problem encountered in our
study was poor patient compliance in completing questionnaires
and attending follow-up visits. This problem, observed also in
other studies, can partially be related to patient selection, as those
surviving less than 3 months are unlikely to comply with the study
requirements. These patients also usually do not benefit from
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outcomes (Medical Research Council Lung Cancer Working Party,
1992; Macbeth et al, 1996; Rees et al, 1997). Furthermore,
obviously not all symptoms were present in all patients, making
statistical analysis more difficult (Bezjak et al, 2002). In future
studies, this problems can perhaps be overcome by the assessment
of ‘index symptom’, that is, the single most troublesome symptom
in each patient, constituting the primary indication for palliative
radiotherapy (Bezjak et al, 2002). It may also be valuable to derive
some aggregated variable lumping scores of key symptoms. In the
current study, however, no difference was observed between
treatment arms in the degree of symptomatic improvement after
radiotherapy, therefore no further, derivate variables assessing the
effect of radiotherapy were analysed.
Our study was carried out between 1997 and 2000. Importantly,
for many of these patients current standard of treatment would
include chemotherapy, which was demonstrated to be effective
both as a sole modality in the palliative setting, and in combination
with radiotherapy in locally advanced NSCLC. The majority of
patients included in current study were not, however, candidates
for combined modality approaches, in particular to curative
therapy (as clearly specified by the inclusion criteria). Some
patients actually received palliative chemotherapy at some time
during the course of their disease, but this could not substantially
influence the main study results.
To conclude, our study confirmed the equal efficacy of shorter
vs longer palliative lung cancer radiotherapy schedules in terms of
palliative effect and treatment tolerance. An improvement in
overall survival was observed in patients treated with 16Gy/2 fr,
confirming the efficacy of this approach. This may hopefully
convince at least some radiation oncologists still using more
protracted regimens to adopt this simple and efficient treatment.
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